methyl 4-methoxy-3-[(trifluoromethanesulfonyl)oxy]benzoate | 573693-07-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-methoxy-3-[(trifluoromethanesulfonyl)oxy]benzoate
• 英文别名: 4-methoxycarbonyl-2-trifluoromethylsulfonyloxyanisole；3-(Trifluoromethylsulfonyloxy)-4-methoxybenzoic acid methyl ester；methyl 4-methoxy-3-(trifluoromethylsulfonyloxy)benzoate
• CAS: 573693-07-9
• 化学式: C₁₀H₉F₃O₆S
• 分子量: 314.239
• InChiKey: CVJAPUJKDOWTFT-UHFFFAOYSA-N

物化性质

• 沸点：
  381.6±42.0 °C(Predicted)
• 密度：
  1.477±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  87.3
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 4-methoxy-3-[(trifluoromethanesulfonyl)oxy]benzoate 在 palladium diacetate 三溴化硼 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 甲苯 为溶剂， 反应 170.0h， 生成 8-Bromo-1,6-dihydroxy-7-methyl-9H-carbazole-4-carboxylic acid methyl ester
  参考文献：
  名称：

  First total synthesis of the neuronal cell protecting carbazole alkaloid carbazomadurin A by sequential transition metal-catalyzed reactions

  摘要：

  从异香兰酸出发，经过九个步骤合成了保护神经细胞的高氧咔唑生物碱咔唑马杜林 A，总收率为 11%。

  DOI：

  10.1039/b301979a
• 作为产物：
  描述：

  3-羟基-4-甲氧基苯甲酸 在 2,6-二甲基吡啶 、 硫酸 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 methyl 4-methoxy-3-[(trifluoromethanesulfonyl)oxy]benzoate
  参考文献：
  名称：

  First total synthesis of the neuronal cell protecting carbazole alkaloid carbazomadurin A by sequential transition metal-catalyzed reactions

  摘要：

  从异香兰酸出发，经过九个步骤合成了保护神经细胞的高氧咔唑生物碱咔唑马杜林 A，总收率为 11%。

  DOI：

  10.1039/b301979a

文献信息

• Transition metals in organic synthesis - Part 83#: Synthesis and pharmacological potential of carbazoles
  作者：Taylor A. Choi、Regina Czerwonka、Ronny Forke、Anne Jäger、Jan Knöll、Micha P. Krahl、Tilo Krause、Kethiri R. Reddy、Scott G. Franzblau、Hans-Joachim Knölker

  DOI：10.1007/s00044-007-9073-0

  日期：2008.6

  the first naturally occurring carbazole alkaloids with antituberculosis (anti-TB) activity, clausine K and micromeline, a study on the structure–activity relationships for anti-TB-active carbazole derivatives has been carried out. The 6-oxygenated carbazoles glycozoline and glycozolinine show antibiotic activity towards several microorganisms. The 7-oxygenated carbazole siamenol exhibits anti-HIV activity

  已经使用铁介导的或钯催化的合成方法制备了具有前景的药理学性质的一系列咔唑衍生物。咔唑生物碱咔唑喹啉C，咔唑马杜林A和B，依巴唑啉A和B，新偶氮他汀B和喹他汀A是作为自由基清除剂的抗氧化剂。因此，它们代表了潜在的先导化合物，用于开发针对由氧衍生的自由基引发的疾病的新型药物。由第一个具有抗结核病（TB）活性的天然咔唑生物碱，克劳斯碱K和微茶碱引发，已开展了抗TB活性咔唑衍生物的结构-活性关系研究。6-氧咔唑糖唑啉和糖唑啉对几种微生物显示出抗生素活性。
• Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity
  申请人：Matsuda Mamoru

  公开号：US20090111807A1

  公开（公告）日：2009-04-30

  An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R 1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R 2 represents a halogen, an alkyl, hydroxyl or alkoxy group, or the like; q represents 0 to 2; R 3 represents hydrogen, an alkyl, alkenyl, alkylcarbonyl or arylcarbonyl group, or the like; R 4 and R 5 independently represent hydrogen, a halogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; R 6 represents hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; A represents an alkylene; R 7 represents OR 8 , NR 8 R 9 , SR 8 , S(O)R 8 , S(O) 2 R 8 ; and X represents O or S.

  本发明的目的是合成一种新的1,2,3,4-四氢喹喔啉衍生物，其化学式表示为（1），并找到该衍生物的药理作用。其中，R1代表卤素、烷基、环烷基、芳基或杂环基等；p表示0至5；R2代表卤素、烷基、羟基或烷氧基等；q表示0至2；R3代表氢、烷基、烯基、烷基羰基或芳基羰基等；R4和R5独立地表示氢、卤素、烷基、烯基、炔基、环烷基、芳基或杂环基等；R6代表氢、烷基、烯基、炔基、环烷基、芳基或杂环基等；A代表烷基；R7代表OR8、NR8R9、SR8、S（O）R8、S（O）2R8；X代表O或S。
• 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：US20130303537A1

  公开（公告）日：2013-11-14

  A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R 1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R 2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R 3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R 4 and R 5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R 6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R 7 represents OR 8 , NR 8 R 9 , SR 8 , S(O)R 8 , S(O) 2 R 8 ; R 8 and R 9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

  以下是由下式表示的1,2,3,4-四氢喹喔啉化合物：在式（1）中，R1表示卤素，烷基，环烷基，芳基或杂环基等取代基；p表示0至5；R2表示卤素，烷基，羟基或烷氧基等取代基；q表示0至2；R3表示氢，烷基，烯基，烷基羰基或芳基羰基等取代基；R4和R5独立地表示氢，卤素，烷基，烯基，炔基，环烷基，芳基或杂环基等取代基；R6表示氢，烷基，烯基，炔基，环烷基，芳基或杂环基等取代基；A表示烷基；R7表示OR8，NR8R9，SR8，S（O）R8，S（O）2R8；R8和R9独立地表示氢，烷基或烯基等取代基；X表示O或S。
• 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP3882239A1

  公开（公告）日：2021-09-22

  The purpose of the present invention is to provide a compound having PIM inhibitory activity. Examples of the present invention include 1,3,4-oxadiazolone compounds represented by the following formula [1], and pharmaceutically acceptable salts, and solvates thereof. The compounds of the present invention have PIM inhibitory activity. In addition, since the compounds of the present invention have PIM inhibitory activity, the compounds of the present invention are useful as therapeutic agents for systemic lupus erythematosus, lupus nephritis, etc.

  本发明的目的是提供一种具有 PIM 抑制活性的化合物。 本发明的实例包括下式[1]代表的 1，3，4-噁二唑酮化合物及其药学上可接受的盐和溶液。 本发明的化合物具有 PIM 抑制活性。此外，由于本发明的化合物具有 PIM 抑制活性，因此本发明的化合物可用作系统性红斑狼疮、狼疮肾炎等的治疗剂。
• NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY
  申请人：Santen Pharmaceutical Co., Ltd

  公开号：EP1995242B1

  公开（公告）日：2012-11-07